STAT6 and cancer: When ECP is used to treat immune-related adverse events in cancer patients due to treatment with immune checkpoint inhibitors, the apoptotic leukocytes induced by ECP are ingested by intestinal macrophages leading to an anti-inflammatory M2-like polarization of macrophages by STAT6 signaling (7).